MDMA-induced changes in within-network connectivity contradict the specificity of these alterations for the effects of serotonergic hallucinogens
This double-blind, placebo-controlled, fMRI study (n=45) found that MDMA induced similar (neuronal) changes as classical (serotonergic) psychedelics.
Authors
- Matthias Liechti
- Stefan Borgwardt
- Friederike Holze
Published
Abstract
It has been reported that serotonergic hallucinogens like lysergic acid diethylamide (LSD) induce decreases in functional connectivity within various resting-state networks. These alterations were seen as reflecting specific neuronal effects of hallucinogens and it was speculated that these shifts in connectivity underlie the characteristic subjective drug effects. In this study, we test the hypothesis that these alterations are not specific for hallucinogens but that they can be induced by monoaminergic stimulation using the non-hallucinogenic serotonin-norepinephrine-dopamine releasing agent 3,4-methylenedioxymethamphetamine (MDMA). In a randomized, placebo-controlled, double-blind, crossover design, 45 healthy participants underwent functional magnetic resonance imaging (fMRI) following oral administration of 125 mg MDMA. The networks under question were identified using independent component analysis (ICA) and were tested with regard to within-network connectivity. Results revealed decreased connectivity within two visual networks, the default mode network (DMN), and the sensorimotor network. These findings were almost identical to the results previously reported for hallucinogenic drugs. Therefore, our results suggest that monoaminergic substances can induce widespread changes in within-network connectivity in the absence of marked subjective drug effects. This contradicts the notion that these alterations can be regarded as specific for serotonergic hallucinogens. However, changes within the DMN might explain antidepressants effects of some of these substances.
Research Summary of 'MDMA-induced changes in within-network connectivity contradict the specificity of these alterations for the effects of serotonergic hallucinogens'
Introduction
Recent fMRI studies of serotonergic hallucinogens such as LSD and ayahuasca have reported widespread decreases in functional connectivity (FC) within resting-state networks (RSNs). These within-network disruptions have been proposed as a specific neuronal mechanism underlying the characteristic subjective effects of hallucinogens, although replication and direct links to subjective experience have been inconsistent. Related work found similar FC changes after administration of selective serotonin reuptake inhibitors (SSRIs), suggesting that monoaminergic stimulation in general might produce such alterations rather than them being unique to classic hallucinogens. Müller and colleagues designed the present study to test whether comparable within-network FC changes can be induced by a non-hallucinogenic, monoaminergic drug. Specifically, they examined acute effects of 125 mg oral MDMA — a potent serotonin, norepinephrine and dopamine releaser — on RSN within-network connectivity and on degree centrality (a graph-based measure of node connectivity). The study therefore assessed whether the FC signatures previously attributed to hallucinogens are specific to 5-HT2A agonism and hallucinogenic subjective effects, or whether they can be produced by broader monoaminergic stimulation.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typeindividual
- Journal
- Compounds
- Topics
- Authors
- APA Citation
Müller, F., Holze, F., Dolder, P., Ley, L., Vizeli, P., Soltermann, A., Liechti, M. E., & Borgwardt, S. (2021). MDMA-induced changes in within-network connectivity contradict the specificity of these alterations for the effects of serotonergic hallucinogens. Neuropsychopharmacology, 46(3), 545-553. https://doi.org/10.1038/s41386-020-00906-2
Related Clinical Trials
References (15)
Papers cited by this study that are also in Blossom
Palhano-Fontes, F., Andrade, K. C., Tófoli, L.F. et al. · PLOS ONE (2015)
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L. et al. · PNAS (2016)
Müller, F., Dolder, P. C., Schmidt, A. et al. · NeuroImage (2018)
Schmid, Y., Enzler, F., Gasser, P. et al. · Biological Psychiatry (2015)
Dolder, P. C., Schmid, Y., Müller, F. et al. · Neuropsychopharmacology (2016)
Rickli, A., Moning, O. D., Hoener, M. C. et al. · European Neuropsychopharmacology (2016)
Quednow, B. B., Kometer, M., Geyer, M. A. et al. · Neuropsychopharmacology (2011)
Preller, K. H., Herdener, M., Pokorny, T. et al. · Current Biology (2017)
Tagliazucchi, E., Roseman, L., Kaelen, M. et al. · Current Biology (2016)
Preller, K. H., Burt, J. B., Adkinson, B. et al. · eLife (2018)
Show all 15 referencesShow fewer
Holze, F., Vizeli, P., Müller, F. et al. · Neuropsychopharmacology (2019)
Dolder, P. C., Müller, F., Schmid, Y. et al. · Psychopharmacology (2017)
Kirchner, K. · Journal of Psychopharmacology (2014)
Nichols, C. D., Nichols, D. E., Johnson, M. W. · Clinical Pharmacology and Therapeutics (2016)
Grob, C. S., Mithoefer, M. C., Brewerton, T. D. · Lancet Psychiatry (2016)
Cited By (19)
Papers in Blossom that reference this study
Jacobs, E., Zahid, Z., Hinkle, J. et al. · BMJ (2026)
Mallaroni, P., Singleton, P., Mason, N. L. et al. · Molecular Psychiatry (2026)
Avram, M., Fortea, L., Wollner, L. et al. · Molecular Psychiatry (2024)
Caspani, G., Ruffell, S. G. D., Tsang, WF. et al. · Pharmacological Research (2024)
Nicol, G. E. · Nature (2024)
Lewis, E. C., Jaeger, A., Girn, M. et al. · Journal of Psychopharmacology (2024)
Erritzoe, D., Timmermann, C., Godfrey, K. et al. · Nature Mental Health (2024)
Girn, M., Rosas, F. E., Daws, R. E. et al. · Trends in Cognitive Sciences (2023)
Singleton, S. P., Wang, J. B., Mithoefer, A. T. et al. · Frontiers in Psychiatry (2023)
Dourron, H. M., Strauss, C., Hendricks, P. S. · Pharmacological Reviews (2022)
Show all 19 papersShow fewer
van Elk, M., Yaden, D. B. · Neuroscience and Biobehavioral Reviews (2022)
Jairaj, C., Rucker, J. · Journal of Psychopharmacology (2022)
Aharon-Almagor, A., Barrett, F. S. · Research Square (2022)
Sarparast, A., Thomas, K., Malcolm, B. et al. · Psychopharmacology (2022)
Vollenweider, F. X., Smallridge, J. W. · Pharmacopsychiatry (2022)
Dursun, S. M., Kelly, J. R., Gillan, C. M. et al. · Frontiers in Psychiatry (2021)
Madsen, M. K., Stenbaek, D. S., Arvidsson, A. et al. · European Neuropsychopharmacology (2021)
Thomas, C. W., Blanco-Duque, C., Breant, B. et al. · Translational Psychiatry (2021)
McCulloch, D. E-W., Madsen, M. K., Stenbæk, D. S. et al. · Journal of Psychopharmacology (2021)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.